异动解读｜Iovance Biotherapeutics盘中上涨18.29%，上调全年营收指引超市场预期

行情直击09-29 21:31

9月29日，Iovance Biotherapeutics盘中上涨18.29%，报12.96美元/股，成交额5088.31万美元。

消息面上，公司最新上调全年营收指引，预计全年营收区间为4.1亿至4.2亿美元，较此前3.5亿至3.7亿美元的指引大幅提升，同时高于FactSet市场一致预期的4.028亿美元。此前公司二季度业绩已大幅超预期，单季营收约9930万美元创历史新高，每股亏损0.11美元优于市场预期的亏损0.13至0.14美元，显示其TIL细胞疗法商业化进展持续加速。

Iovance Biotherapeutics是一家生物技术公司，专注于利用自体肿瘤浸润淋巴细胞（TIL）开发和商业化针对转移性黑色素瘤等实体瘤的细胞治疗方法。

（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/1121733946?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-09-29 21:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1121733946","market":"hk","top_or_hot":-1,"title":"异动解读｜Iovance Biotherapeutics盘中上涨18.29%，上调全年营收指引超市场预期","media":"行情直击","content":"<p><p>9月29日，Iovance Biotherapeutics盘中上涨18.29%，报12.96美元/股，成交额5088.31万美元。</p><p>消息面上，公司最新上调全年营收指引，预计全年营收区间为4.1亿至4.2亿美元，较此前3.5亿至3.7亿美元的指引大幅提升，同时高于FactSet市场一致预期的4.028亿美元。此前公司二季度业绩已大幅超预期，单季营收约9930万美元创历史新高，每股亏损0.11美元优于市场预期的亏损0.13至0.14美元，显示其TIL细胞疗法商业化进展持续加速。</p><p>Iovance Biotherapeutics是一家生物技术公司，专注于利用自体肿瘤浸润淋巴细胞（TIL）开发和商业化针对转移性黑色素瘤等实体瘤的细胞治疗方法。</p><p>（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>异动解读｜Iovance Biotherapeutics盘中上涨18.29%，上调全年营收指引超市场预期</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n异动解读｜Iovance Biotherapeutics盘中上涨18.29%，上调全年营收指引超市场预期\n</h2>\n\n<h4 class=\"meta\">\n\n2026-09-29 21:31 北京时间&nbsp;&nbsp;&nbsp;<strong>行情直击</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>9月29日，Iovance Biotherapeutics盘中上涨18.29%，报12.96美元/股，成交额5088.31万美元。消息面上，公司最新上调全年营收指引，预计全年营收区间为4.1亿至4.2亿美元，较此前3.5亿至3.7亿美元的指引大幅提升，同时高于FactSet市场一致预期的4.028亿美元。此前公司二季度业绩已大幅超预期，单季营收约9930万美元创历史新高，每股亏损0.11美元优于...</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IOVA","symbol_name":"Iovance Biotherapeutics, Inc.","start_time":0,"source_url":"","article_id":"1121733946","we_media_id":"1059448697","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1121733946","pubTimestamp":1790688687,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"行情直击","introduction":"个股异动一手消息解读","home_visible":1,"id":"1059448697","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"9月29日，Iovance Biotherapeutics盘中上涨18.29%，报12.96美元/股，成交额5088.31万美元。消息面上，公司最新上调全年营收指引，预计全年营收区间为4.1亿至4.2亿美元，较此前3.5亿至3.7亿美元的指引大幅提升，同时高于FactSet市场一致预期的4.028亿美元。Iovance Biotherapeutics是一家生物技术公司，专注于利用自体肿瘤浸润淋巴细胞开发和商业化针对转移性黑色素瘤等实体瘤的细胞治疗方法。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IOVA":"Iovance Biotherapeutics, Inc."},"translate_title":"Unusual Movement Analysis | Iovance Biotherapeutics rose 18.29% intraday after raising its full-year revenue guidance to exceed market expectations.","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IOVA":1},"content_text":"9月29日，Iovance Biotherapeutics盘中上涨18.29%，报12.96美元/股，成交额5088.31万美元。消息面上，公司最新上调全年营收指引，预计全年营收区间为4.1亿至4.2亿美元，较此前3.5亿至3.7亿美元的指引大幅提升，同时高于FactSet市场一致预期的4.028亿美元。此前公司二季度业绩已大幅超预期，单季营收约9930万美元创历史新高，每股亏损0.11美元优于市场预期的亏损0.13至0.14美元，显示其TIL细胞疗法商业化进展持续加速。Iovance Biotherapeutics是一家生物技术公司，专注于利用自体肿瘤浸润淋巴细胞（TIL）开发和商业化针对转移性黑色素瘤等实体瘤的细胞治疗方法。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1121733946","isCrawlerRequest":true}